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Correction to: British Journal of Cancer 2003; 89 (S1), S9–S11 doi: 10.1038/sj.bjc.6601078
Unfortunately, due to an error, the tables were omitted from the
above article.
All the three tables (Table 1–3) are reprinted below:
The publisher would like to apologise for any inconvenience this
error may have caused.
Table 1 Range of NICE guidance affecting patients with cancer
Technology appraisals
Drugs (Paclitaxel, Docetaxel, Trastuzumab, Vinorelbine, Topetecan, Caelyx, Temozolamide, Irintecan, Oxaliplatin, Raltitexed, Gemcitabine, Vinorelbine, Fludarabine,
Imatinib)
Liquid-based cytology
Laparoscopic surgery for colorectal cancer
Clinical guidelines
Lung cancer
Familial breast cancer
Cancer service guidances
Breast, urology, haematico-oncological, colorectal, head and neck, child and adolescent, brain and cns, skin, supportive and palliative care
Cancer referral guidance
Confidential enquiries
Review of cancer care in acute units
Table 2 Key principles underlying the Institute’s clinical guidelines
NICE clinical guidelines should:
K aim to improve the quality of clinical care
K address the clinical effectiveness of treatments or management approaches (that is, how well treatments or management approaches work)
K address the cost effectiveness of treatments or management approaches
K be advisory
K be developed through a process that considers all those who might be affected by the guideline (usually including healthcare professionals, patients and their carers,
service managers, the wider public, Government and the healthcare industries)
K be based on the best possible research evidence and professional consensus
K be developed using methods that command the respect of patients, the NHS and NHS stakeholders
K be developed with the involvement of patients and healthcare professionals
K set out the clinical care that might reasonably be expected throughout the NHS in England and Wales
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www.bjcancer.comTable 3 The three versions of the clinical guideline
1. NICE GUIDELINE (SHORT VERSION)
This uses a standard template, and contains:
K the Institute’s guidance to the NHS
K implementation advice
K audit advice
K information on the expected impact on NHS resources
K a review date
K a clinical practice algorithm
K details of the Guideline Development Group members
2. NATIONAL COLLABORATING CENTRE GUIDELINE (FULL VERSION)
This includes:
K the recommendations
K the profile of treatments and interventions assessed by the Guideline
Development Group
K a description of how the evidence was collected, reviewed and assessed
K a description of how the recommendations were formulated and graded
K full reference details of the literature in the evidence base
K details of the Guideline Development Group members
K names of the stakeholders who commented on the first draft of the guideline
3. INFORMATION FOR THE PUBLIC (PATIENT VERSION)
This version:
K interprets the recommendations made in the NICE Guideline for patients and
carers
K aims to help patients to make informed choices about their care
K can be reproduced in patient/carer organisations’ own material, with the
permission of the Institute
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